---
title: "Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278774326.md"
description: "Phase 1 of the clinical trial FHD-909 (LY4050784) is progressing according to schedule, with a primary focus on SMARCA4 (BRG1)-mutant cancers, particularly non-small cell lung cancer (NSCLC). The trial involves gradually increasing the dosage to determine the optimal level. This study aims to evaluate the efficacy and safety of the treatment in patients with these specific mutations. The trial is significant for potentially offering a new therapeutic option for patients with SMARCA4 mutations, particularly those with NSCLC."
datetime: "2026-03-11T20:11:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278774326.md)
  - [en](https://longbridge.com/en/news/278774326.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278774326.md)
---

# Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Phase 1 of the clinical trial FHD-909 (LY4050784) is progressing according to schedule, with a primary focus on SMARCA4 (BRG1)-mutant cancers, particularly non-small cell lung cancer (NSCLC). The trial involves gradually increasing the dosage to determine the optimal level. This study aims to evaluate the efficacy and safety of the treatment in patients with these specific mutations. The trial is significant for potentially offering a new therapeutic option for patients with SMARCA4 mutations, particularly those with NSCLC.

### Related Stocks

- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FHTX.US](https://longbridge.com/en/quote/FHTX.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [BUZZ-Cancer biotech Adlai Nortye jumps after $150 mln equity financing](https://longbridge.com/en/news/282996483.md)
- [BUZZ-Allogene tumbles on $175 mln stock offering after cancer therapy data](https://longbridge.com/en/news/282722450.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)
- [HUTCHMED to Unveil New ATTC and Surufatinib Data at AACR 2026](https://longbridge.com/en/news/282114975.md)
- [BUZZ-Precision BioSciences up as hepatitis B gene‑editing trial expands in Europe](https://longbridge.com/en/news/282832865.md)